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Simple Summary: Radiogenomics enables prediction of the status and prognosis of patients using
non-invasively obtained imaging data. Current machine learning (ML) methods used in radio-
genomics require huge datasets, which involve the handling of large heterogeneous datasets from
multiple cohorts/hospitals. In this study, two different glioma datasets were used to test various
ML and image pre-processing methods to confirm whether the models trained on one dataset are
universally applicable to other datasets. Our result suggested that the ML method that yielded the
highest accuracy in a single dataset was likely to be overfitted. We demonstrated that implemen-
tation of standardization and dimension reduction procedures prior to classification, enabled the
development of ML methods that are less affected by the multiple cohort difference. We advocate
using caution in interpreting the results of radiogenomic studies of the training and testing datasets
that are small or mixed, with a view to implementing practical ML methods in radiogenomics.
Abstract: Radiogenomics use non-invasively obtained imaging data, such as magnetic resonance
imaging (MRI), to predict critical biomarkers of patients. Developing an accurate machine learning
(ML) technique for MRI requires data from hundreds of patients, which cannot be gathered from
any single local hospital. Hence, a model universally applicable to multiple cohorts/hospitals is
required. We applied various ML and image pre-processing procedures on a glioma dataset from The
Cancer Image Archive (TCIA, n = 159). The models that showed a high level of accuracy in predicting
glioblastoma or WHO Grade II and III glioma using the TCIA dataset, were then tested for the
data from the National Cancer Center Hospital, Japan (NCC, n = 166) whether they could maintain
similar levels of high accuracy. Results: we confirmed that our ML procedure achieved a level of
accuracy (AUROC = 0.904) comparable to that shown previously by the deep-learning methods
using TCIA. However, when we directly applied the model to the NCC dataset, its AUROC dropped
to 0.383. Introduction of standardization and dimension reduction procedures before classification
without re-training improved the prediction accuracy obtained using NCC (0.804) without a loss
in prediction accuracy for the TCIA dataset. Furthermore, we confirmed the same tendency in a
model for IDH1/2 mutation prediction with standardization and application of dimension reduction
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that was also applicable to multiple hospitals. Our results demonstrated that overfitting may occur
when an ML method providing the highest accuracy in a small training dataset is used for different
heterogeneous data sets, and suggested a promising process for developing an ML method applicable
to multiple cohorts.
Keywords: glioma; machine learning; radiogenomics; IDH; MGMT
1. Introduction
Magnetic resonance imaging (MRI) is widely used for cancer diagnoses. It is most
frequently used to diagnose the pathology of brain tumors [1,2]. Besides conventional
diagnostic information, MRI data may also contain phenotypic features of brain tumors,
which are potentially associated with the underlying biology of both the tumor and the
patient [3,4]. Thus, MRI is drawing attention as a source of information that may be utilized
to predict genomic or clinical backgrounds of brain tumor patients, leading to the develop-
ment of treatment strategies [2]. This field of research is termed “radiogenomics” [5].
Glioma presents a predominant target for radiogenomics, because identification of
biomarkers that may help improve glioma patient outcomes is considered to be an urgent
task [2,6,7]. WHO Grade IV glioblastoma (GBM), in particular, results in distinctly severe
outcomes, compared to other WHO Grade II and III gliomas (lower grade gliomas: LrGG)
and the five-year survival rate of GBM is as low as 6.8%, while that of LrGG is higher
such as 51.6% for diffuse astrocytoma or 82.7% for oligodendroglioma [8]. Recent reports
indicate that numerous genetic mutations may play a role in the heterogeneity of gliomas.
The molecular landscape has been remarkably transformed by the detection of key genetic
mutations or epigenetic modifications, such as IDH1 and IDH2 mutations, the TERT pro-
moter mutation, chr1p/19q codeletion, and O-6-Methylguanine-DNA methyltransferase
(MGMT) promoter methylation [7]. IDH1 and IDH2 mutations (hereafter referred to as
IDH mutation) are mutually exclusive “truncal mutations”, which are frequently associated
with better prognoses for gliomas, such as Grade II and Grade III gliomas, and thereby
considered as prognostic factors for gliomas [9,10]. MGMT promoter methylation status is
also known to be a prognosis factor of GBM associated with temozolomide, which is used
as a first-line, standard chemotherapeutic agent for GBM patients.
In addition, recently, the WHO grading system of central nervous system tumors
was updated to require genetic testing including IDH mutation, TERT promoter mutation,
H3K27M mutation, 1p/19q codeletion for the precise diagnosis of gliomas. Currently
these amendments can offer better understanding of glioma biology, but also raise a new
problem that all the tumor tissues supposed to be a glioma should be ideally taken by
surgery or biopsy and analyzed for genetic testing, but not all countries have enough
pathological diagnosis capacity. As such, it is clinically useful if genetic backgrounds could
also be obtained at the same time when the first pre-operative images of glioma patients
are captured.
Glioma is a rare cancer and, therefore, the number of patients at any given hospital is
not necessarily large. Some large public databases, such as The Cancer Imaging Archive
(TCIA) GBM and LGG [6] or Repository of Molecular Brain Neoplasia Data (REMBRANDT)
were published [11] in order to enhance radiogenomic studies targeting glioma. Many
recent studies have applied a wide variety of machine learning (ML) methods from volu-
metric features to cutting-edge deep learning (DL) methods, in order to predict the grade
and grouping of tumors [12,13], including IDH mutation [14,15], MGMT methylation sta-
tus [16–21], survival [22–26], as well as other combinations of patient backgrounds [27–34].
On the other hand, studies using local datasets showed significant diversity in prediction
accuracy for the same prediction target. For example, radiogenomic features are found
to predict MGMT methylation status with 83% accuracy using deep learning [28], al-
though another study achieved the accuracy only around 62% for the same data source [35].
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While numerous studies have validated the robustness of gene expression signatures
for GBM [15,36], only a few have used multiple datasets from different sources [32,37].
Although, based on radiomic image features, these studies could not show consistent
improvement in prediction accuracy without mixing cohorts, or using datasets where the
number of patients was not sufficient to reduce the variance of classification performances
obtained by cross validation. Furthermore, most studies examine the prediction accuracy
of the best methods within one dataset and do not show the results from the viewpoint
of the performance stability across the datasets, particularly for the difference between
public anonymized dataset and local data [38]. The reproducibility of radiogenomic studies
has already gathered attention for the evaluation of different preprocessing strategies and
tumor annotations [39,40]. Image data that depend on the hospital-specific MRI sequence
parameters or image processing for analyses tend to have many systematic and inevitable
differences, called batch effects [41,42]. A spatial standardization, which is an approach to
scale each brain image to a reference brain, is one promising way to reduce the impact of
the systematic differences, while even the choice of standardization is impactful for the
performance stability [43]. This raises a query as to whether a model developed using
images obtained from a public database, which are generally pre-processed for anonymiza-
tion, is applicable to images obtained from a local hospital in a practical way. This type of
problem is the main subject of transfer learning in the ML domain because re-training of
the entire models demands a huge resource as well as annotated training data from a local
hospital [44].
The objective of the present study is to identify the important factors to establish ML
models that exhibit a high level of performance, not only in a single-cohort, but also in other
hospital datasets. We examined the stability of prediction accuracy using two different MRI
datasets, wherein the public TCIA dataset was used to generate a model, which was then
directly applied to the National Cancer Center Hospital Japan (NCC) dataset. Because the
public dataset is already preprocessed, this comparison gives us the clarification whether
the trained model is still effective for datasets from local hospitals beyond the various
hospital or cohort-specific biases. According to our results, the best model is shown to
suffer from the over-fitting problem for another dataset, especially when the model does
not include either standardization or dimension reduction processes. It would be a robust
and practical solution to choose the better model from multiple models trained for the
public dataset using a partially annotated local dataset.
2. Materials and Methods
2.1. TCIA and NCC Cohort
This study was approved by the National Cancer Center Institutional Review Board
(study number: 2013-042). The NCC cohort dataset consisted of MRI scans, clinical in-
formation, and genomic information collected from 90 GBM and 76 LrGG patients who
were treated at NCC between 2004 and 2017. Patient information is summarized (Table 1
and Supplementary Table S1). MRI data contained 4 widely used data types as follows:
T1-weighted imaging (T1WI); gadolinium-enhanced T1-weighted imaging (Gd-T1WI);
T2-weighted imaging (T2WI); and fluid-attenuated inversion recovery (FLAIR) sequence.
All images were acquired in an axial direction with thicknesses in the range of 4–6 mm.
As another cohort, the public image and background data of 102 GBM and 65 LGG
patients were obtained from the training dataset of Brain Tumor Segmentation (BraTS)
challenge 2018 [6], which is based on TCIA information. This public dataset is constructed
for the contest of brain tumor segmentation methods and will hereafter be referred to as the
TCIA dataset. The images were already co-registered, skull-stripped, and re-sampled to a
size of 240 × 240 × 155. The genomic and clinical information from these were described
previously [45]; (Table 1 and Supplementary Table S1). Patients with a set of at least 3 types
of MRI scans, tumor annotation, and genomic information were selected.
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Table 1. Demography of glioma patients in two different datasets used in this study, The Cancer
Image Archive (TCIA) and National Cancer Center Hospital Japan (NCC). Each row represents the
statistics or number of people assigned to each category for GBM and lower grade glioma patients.
For genomic alterations, the number of people carrying IDH mutations, TERT promoter mutations,
chr 1p19q codeletions, and higher levels of MGMT promoter methylation was separated from those
of others via slash.
TCIA NCC
GBM LGG GBM LwGG
Total 102 65 90 76
Age (average) 57.5 44.0 61.9 45.5
Gender (F/M) 32/55 38/27 39/51 29/47
KPS (average) 80.4 90.0 76.6 86.7
IDH mut vs wt 4/66 53/11 6/84 52/22
TERT mut vs wt 3/1 21/40 55/35 33/43
chr1p19q codel 0/83 13/52 2/48 25/50
MGMT met H vs L 20/29 52/13 34/56 46/30
The data provided by Arita et al., which consisted of IDH1/2 mutations, codeletion of chromosome 1p and 19q
(1p19q codeletion), TERT promoter mutations, and MGMT methylation, were used to represent the genomic and
epigenomic features of the NCC dataset [7]. All values were binarized according to a previous study.
2.2. Region of Interest (ROI) Extraction
Tumor regions of the NCC cohort dataset were examined by a skilled radiologist (MM),
who has been practicing for 18-years, using ImageJ [46]. For all 4 MRI types, 2 categories of
ROI information tumor (enhanced in Gd-T1WI) region and edema (high intensity lesion in
T2WI and FLAIR) were contoured via single strokes. Image features were computed for
the region inside of the outline. ROIs were also transformed via realigning, co-registering,
and normalizing in the same manner. Tumor and edema ROI of the TCIA dataset were
provided by BraTS. Pixels annotated as “necrosis” or “enhancing tumor region” were
labeled as tumor, and regions annotated as “necrosis”, “edema”, “non-enhancing tumor”,
and “enhancing tumor region” were treated as edema ROI, which corresponds to the
edema region and its inside. All results for features computed for tumor ROI or without
ROI are shown in Supplementary Figures S1–S5.
2.3. Preprocessing of Brain Images
NCC-derived MRI data was converted from digital imaging and communications in
medicine (DICOM) to the Neuroimaging Informatics Technology Initiative (NIfTI) format
with neurological space, using SPM12 [47]. Skull-stripping was carried out via the stan-
dard_space_roi command in FSL-BET library [48]. For the TCIA dataset, we applied normal-
ization and brain standardization to the downloaded MRI data in the NIfTI format that was
already skull-stripped and resampled after normalization and anonymization processes.
Two frequently used spatial standardization procedures were applied to adjust dif-
ferences in individual brain sizes and shapes; one was Tissue Probability Maps (TPM)
in MNI space using SPM12 (referred to SPM), while the other was average brain space
compiled by MICCAI multi atlas challenge data using ANTs [49]. We also applied two
normalization methods to regulate differences in pixel brightness. Details pertaining to an
entire standardization, such as pixel normalization, mapping, and skull-stripping processes
are shown in Supplementary Material.
2.4. Calculating Image and Patient Features for ML
To examine the classification efficiency of a wide variety of image features, a maxi-
mum of 16,221 features were generated for each patient, using both images and clinical
records for the following ML training and prediction classifiers. Identical procedures
were applied to both the NCC cohort and the TCIA dataset. The features are summa-
rized below, where M represents the number of features generated in each category (see
Supplementary Materials).
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1. Basic features (MRI scans; M = 28 × 4): statistics of pixel values from 4 types of
MRI scans. Twenty-eight features were generated from each MRI type, consisting
of percentile pixel values of the ROI as well as whole brain regions as a control
with steps increasing by 10%. Several other statistics, such as mean, median, min,
max, dimension size (x, y, z), and centroid coordinates of the whole brain were also
included to control patient-specific image pattern.
2. Pyradiomics-based features (MRI scans; M = 960 × 4): first order statistics, shapes, and
textures were calculated by pyradiomics (v2.1.0), which is frequently used software
for radiomic analysis [3]. Pyradiomics was used for radiomic feature extraction from
2D and 3D images with ROI information. All parameters were computed except for
NGTDM due to the long running time.
3. Pre-trained DL-based features (MRI scans; M = 3072 × 4): the DL model Inception-
ResNet v2, pre-trained on ImageNet database, was used to obtain general image
features. Outputs of the second to last layer were used as image features. Because the
number of slices containing tumors was different for each patient, averages and sums
of the outputs along the z-axis were calculated.
4. Anatomical tumor location (MRI scans; M = 30): a vector representing occupancies
of each anatomical region calculated via FSL (v5.0.10) [48] was used to represent
information pertaining to 3D tumor position.
5. Clinical information (M = 3): features of each patient, such as sex, age, and Karnofsky
Performance Status (KPS) were used as additional features.
Most image features were computed only for edema (tumor, or all brain) regions,
while basic features contained the metrics for both edema and whole image. In addition, the
computation of DL-based features used rectangular images to cover all target tumor regions
with the margin of 1 pixel using the command line tool “ExtractRegionFromImageByMask”
included in the ANTs library [49]. The results shown in the main script were obtained
using edema ROIs because of the high prediction performances. Those with tumor ROIs
and without ROIs are found in Supplementary Figures S1–S5.
2.5. Feature Selection and Dimension Reduction Methods
One feature selection and two-dimension reduction methods were tested to demon-
strate the efficacy of feature generation for transfer learning on radiogenomics. Logistic
regression with L1 regularization and linear discriminant analysis, with the maximum
number of features set to 200, was used for feature selection. Principal component analysis
(PCA) and non-negative matrix factorization (NMF) were used as dimension reduction
methods. PCA and NMF approximate input data into the low-dimensional matrices, where
the dimension of the column or the row is a user-defined value, thereby reducing noise
and integrating similar features into a single dimension. In both methods, the number of
dimensions following decomposition was set to 8, 20, 40, and 200, in order to extract the
primary features in the 4 MRI scan types. These analyses were implemented using Python
3 scikit-learn library.
2.6. Classification and Performance Evaluation for ML Classifiers
In order to evaluate the robustness of ML classifiers to dataset differences, widely-
used and accurate ML classifiers were applied to the classification procedure as follows:
random forest, k-nearest neighbor (with k set to 1, 3, and 5), support vector machine, linear
discriminant analysis, AdaBoost, and XGBoost. For purposes of classification, feature
vectors were applied without normalization to avoid effects of patient imbalance on each
dataset. Five-fold cross validation was performed for the TCIA dataset in order to evaluate
these methods. Next, in order to select the best-fit model for NCC, the model was applied to
half of the NCC data that had been randomly sampled to validate each prediction problem
(referred to as NCC validation). Lastly, the final accuracy of the model was estimated using
the remaining half of the NCC data (NCC test). The area under the receiver operating
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characteristic curve (AUROC) represented the measure of accuracy used to evaluate the
general robustness of the models.
2.7. Publicly Available Brain Image Analysis Toolkit (PABLO)
The scripts used in this study are available at our repository, named PABLO (https:
//github.com/carushi/PABLO, accessed on 14 June 2021). PABLO is a versatile platform
for analyzing combinations of methods, consisting of three steps widely used in MRI anal-
ysis; (1) standardization; (2) dimension reduction; and (3) classification. Standardization
projects a patient head shape to the single standard to alleviate the individuality of brain
images with adjusting the distribution of pixel brightness. Dimension reduction extracts or
generates important features from the data, often resulting in stable classification results.
3. Results
Statistics of patients in the TCIA and NCC datasets are shown in Table 1. Both datasets
displayed similar tendencies in terms of the number of GBM/LrGG, mutations and epige-
nomic status. On the other hand, the distribution of image feature values indicated that
the distributions of the two datasets were clearly separated regardless of the property of
patients (Figure 1). High-dimensional image features from each patient were calculated
according to standard MRI analysis methods as described in Materials and Methods, and
visualized in two dimensions via t-SNE [50]. While both TCIA and NCC datasets con-
tained information from GBM, as well as LrGG patients, it is indicated that the patients
were clustered according to the datasets that were obtained rather than their phenotypic
properties, suggesting that the model generated for TCIA may not accurately work for
NCC without additional training.
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Figure 1. An overview of the dataset preprocessing and analytical methods used in this study. (A) Brain image data is
applied to the multiple preprocessing steps; standardization of brain shape, pixel normalization, and skull-stripping. Then
image features for radiogenomics are computed. To test the robustness of the trained models, we separated the whole
NCC dataset to two independent partial NCC dataset: NCC validation and test set. The embedding space for dimension
reduction is obtained from the TCIA dataset and applied to the partial NCC datasets independently. (B) In a machine
learning workflow, all ML models were generated from TCIA data. The models were applied to TCIA (for cross validation),
with half of the NCC data used for validation (termed NCC validation or NCC valid) and the other half of the NCC data
(NCC test).
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The application workflow of our ML procedures is depicted (Figure 2). In order
to generate an ML procedure for the ML model that is sufficiently accurate for use in
multiple cohorts or datasets, we developed a novel pipeline, termed PABLO. The purpose
of classification was to generate a discriminative model between GBM/LrGG and other
mutation/epigenetics types.
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On the other hand, a model that is trained for TCIA and shows the highest accuracy
in cross validation does not always achieve a high accuracy on other cohorts. The grey
and orange bars seen in Figure 3 indicate the accuracies obtained when the best models
developed in TCIA were applied to the NCC validation and test set (0.383 and 0.392,
respectively), showing a significant decrease in accuracy for both cases.
Next, we applied standardization of brain shape prior to image feature computation,
which was used to improve the accuracy of the model for radiogenomics in multiple
cohorts. The accuracies obtained when two spatial standardization platforms SPM and
ANTs were applied are compared with those without standardization for GBM and IDH
prediction (Figure 4A,B). As with the case without standardization methods, the accuracies
obtained for GBM prediction within the TCIA dataset were higher than 0.9 with SPM and
ANTs, while those obtained via NCC changed drastically, depending on the standardization
method used. In particular, the accuracy obtained via the SPM standardization method
remained higher than 0.80, indicating that standardization may enhance applicability of a
model to multi-cohort analyses. The accuracies estimated for IDH prediction also showed a
similar tendency to those for GBM prediction. As such, it is suggested that standardization
may improve the generalization performance of the generated model.
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Dimension reduction is another pre-processing procedure to extract or generate lower
dimensions representing the differences between different classes, such as GBM/LrGG
or IDH mutation, beyond cohort differences. For the purpose to examine the influence
of dimension reduction, simple feature selection methods, PCA, and NMF with varying
the dimension size were performed before the classification (Figure 4C,D). All accuracies
obtained for both prediction targets were high for TCIA when using dimension reduction
methods. However, the accuracies for NCC test and validation using PCA and NMF
showed substantially higher performances than those via feature selection in GBM predic-
tion. For IDH prediction, the accuracies of NMF were higher than those of the others. These
results indicate that dimension reduction has the potential to reduce the cohort-specific
systematic differences and increase the accuracy for NCC (even when the model was
generated using the TCIA dataset only).
However, the model that achieved the highest accuracy for TCIA still did not achieve
the highest accuracy for the NCC dataset, even after classification and dimension reduction
were applied. Thus, we next assume a practical situation where a part of the local dataset, or
NCC validation, is available to select a robust model among the generated models for TCIA.
The accuracies of the two models are compared for the TCIA, NCC validation, and NCC
test set to show which model is the best for the NCC test set (Figure 5). In either case, the
model selected by the TCIA result was not the best, but worse for the NCC dataset, while
the best model for the NCC validation set produced comparable accuracies for the TCIA
dataset. As such, selecting the most robust model among all generated models according
to their performances for partial validation data only is suggested to be an efficient way to
obtain comparable prediction accuracy, even though the models are not re-trained for the
new dataset.
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We further tested whether the accuracies showed similar tendencies even after clinical
information was integrated into the radiomic features. We combined image information
with clinical information, such as sex, age, and KPS, for classification, and examined the
changes in accuracy in the same manner shown in Figures 3–5. Accuracies that were
obtained using different standardization methods for GBM and IDH prediction are shown
(Figure 6A,B). First, the accuracies obtained via TCIA and NCC overall tend to be higher
than those obtained usi g only image information, indicating the si nificant contribution
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made by clinical information. In addition, the accuracies were less sensitive for the differ-
ence of the standardization methods used. Similar calculations performed for dimension
reduction methods are shown (Figure 6C,D). These results indicated that while combining
image features with clinical information substantially increased prediction performance,
dimension reduction was not sufficiently effective in bringing about improvement as much
as that shown in classification based on image features alone.
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standardization and dimension reduction methods. The difference of this figure from Figure 4 is that input data comprised
images as well as clinical information, whereas in Figure 4 only image features are used. (A,B) Comparison of accuracies due
to differences in the standardization method for GBM and IDH prediction, respectively. (C,D), Comparison of accuracies
due to differences in dimension reduction methods for GBM and IDH prediction, respectively.
However, the importance of standardization and dimension reduction was revealed
when the accuracies were compared between the models, showing the highest accuracy
for the TCIA and NCC validation set (Figures 5 and 7). As a result, the selected models
that showed the best accuracy for the NCC validation dataset were based on both SPM for
standardization and NMF for dimension reduction. This result suggests that a combination
of standardization and dimension reduction may enhance the stability and reproducibility
of predictions based on image features and clinical information across the different cohorts,
such as the public training dataset and test set from local hospitals.
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4. Discussion
Radiogenomics is a rapidly developing field of research to predict the genetic back-
grounds of neoplasms, including gliomas using medical images including computed
tomography, MRI, and ultrasound, among others [51,52]. Precise diagnoses for gliomas
require surgically obtained specimens for further investigation of immunohistochemistry,
fluorescence in situ hybridization, and DNA sequencing. Although it is reported that
the extent of resection (particularly when close to complete resection) is associated with
better prognoses in GBM [53], the extent of resection was not prognostic for IDH 1/2
mutant and 1p/19q co-deleted tumors, which are known to be sensitive to chemotherapy
as well as radiotherapy [54,55]. Hence, the potential impact of radiogenomics is that it
offers a non-invasive method to predict these genetic markers important for diagnosis and
prognosis. In fact, the WHO classification of tumors will be updated soon, in 2021, and
include the need of analysis for chromosome 7 and loss of whole chromosome 10, and
TERT promoter mutation and EGFR amplification for the diagnosis of glioblastoma even
though the tumor has histologically low grade glioma features. Therefore, the importance
of genetic background detection is increasing along with the discovery of more genes
involved in modulating the tumor growth. Recent studies revealed the heterogeneity of
genetic background within the tumor, which is expected to be decoded by radiogenomic
studies [56].
The objective of this study was to discover important factors to establish a classifier
that is able to perform better, not only in the context of single-cohort cross validation,
but also when the model is used in other hospitals. Due to requirements associated with
maintaining confidentiality regarding patient images and clinical information, we assumed
a general situation, where the classifier was required to be applicable to a local dataset,
using parameters trained only by a public dataset. Classification accuracies obtained via
cross validation in TCIA were notably higher than those obtained by applying the model
to either of the NCC validation or test sets, indicating a loss of generality in the model
generated and selected from the TCIA dataset (Figures 6 and 8). However, the findings
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also showed the presence of models having accuracies that were similar to those of the
best models, demonstrating that pre-processing via brain-embedding yielded a much more
robust model over cohorts/hospitals and clinical information was as important as image
data. Thus standardization and dimension reduction, particularly for the combination of
SPM and NMF, have potential to generate models that can be used over multiple hospitals.
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TCIA, NCC validation, and NCC tests, respectively.
In addition to investigating different pre-processing and dimension reduction pro-
cedures, we also analyzed different brightne s standardization methods an d termined
that changes in brightness id not compl tely fill the gap between TCIA and NCC images.
Furthermore, th effect of ROI information was investigated and the results indicated that
using tumor ROI id not improve prediction accuracies for IDH and MGMT mu ations in
GBM patients (Supplementary Figures S1 and S2). Prediction accuracies obtained without
ROI information showe diff rent tendencies for TCIA and N C d tasets. While accuracy
obtained via cross validation was hig er t . f r B and IDH prediction in TCIA, the
highest accuracy models obtained via the NCC dataset were only 0.4-0.6 AUROCs, regard-
less of the pre-processing methods used (Supplementary Figures S3–S5). This suggested
the importance of using edema ROI information based on classical radiomic features for
prediction improvement across cohorts. The classification performances of each single
feature are also varied, depending on the source data types. Hence, the classification
performance of each feature may be substantially changed according to the input and ROI
(Supplementary Figure S6).
Furthermore, we examined the differences in accuracy associated with different ML
classifiers and determined that the higher the accuracy of the model trained and evaluated
on the same dataset was, the lower the accuracy of the model tested on the different dataset
(Supplementary Figure S7). In addition, the procedures without dimension reduction
methods tended to yield a lower accuracy for cross-dataset applications instead of a
higher accuracy via cross validation, compared to the ones with dimension reduction
methods, indicating the overfitting potential of each ML classifier in the cases without
dimension reduction.
5. Conclusions
In this study, we performed a comprehensive assessment of radiogenomic classifi-
cation models using two glioma datasets that are suffering from systematic biases for
hospitals involved in the dataset acquisition and image pre-processing. Our results suggest
that the ML method that yielded the highest accuracy in a single dataset was likely to be
overfitted and showed the severe decrease of prediction accuracies for another dataset.
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We further tested the impact of the implementation of standardization and dimension
reduction procedures prior to classification. As a result, it enabled the development of
ML methods that are less affected by the cohort differences. Our results advocate using
caution in evaluating the accuracy of radiogenomic ML models in which the training
and testing datasets are small or mixed, with a view to implement practical ML methods
in radiogenomics.
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10.3390/cancers13143611/s1, Supplementary document: PDF document including the details of
methods and supplementary data, Figure S1: AUROCs based on tumor ROI, Figure S2: the best
models based on tumor ROI, Figure S3: AUROCs without ROI information with different stan-
dardization methods, Figure S4: AUROCs after applying dimension reduction methods without
ROI information, Figure S5: the best models without ROI information, Figure S6: Comparison of
classification performances of each pair of feature and image type by cross validation using the NCC
dataset, Figure S7: Comparison of eight machine learning classifiers for the whole NCC dataset,
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